Risk Factors and the Effect of Plasma Exchange on Prognosis of Pregnancy-related Thrombotic Microangiopathies
"Risk Factors for Pregnancy-related Thrombotic Microangiopathies Retrospective Study of the Effect of Plasma Exchange on Prognosis of Pregnancy-related Thrombotic Microangiopathies"
1 other identifier
observational
50
0 countries
N/A
Brief Summary
Early identification of the risk factors of pregnancy-related thrombotic microangiopathies can help us reduce the complications of such patients and increase the survival rate of patients. In addition, it is still controversial whether patients with pregnancy-related thrombotic microvessels should receive plasma therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2021
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 29, 2021
CompletedFirst Posted
Study publicly available on registry
July 2, 2021
CompletedStudy Start
First participant enrolled
August 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2022
CompletedJuly 2, 2021
June 1, 2021
1 year
June 29, 2021
June 29, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
TMA happen
pregnancy associated thrombotic microangiopathy happen or not at 28th day after ICU admission
28th day after ICU admission
Secondary Outcomes (3)
renal function
28th day after ICU admission
platelet level
28th day after ICU admission
survival rate
28th day after ICU admission
Study Arms (3)
No TMA
parturients without thrombotic microangiopathies
TMA with plasma exchange
parturients with thrombotic microangiopathies, and treated with plasma exchange
TMA without plasma exchange
parturients with thrombotic microangiopathies, but not treated with plasma exchange
Interventions
Plasma exchange was performed daily for five times or until platelet level returned to normal
Eligibility Criteria
Pregnant patients admitted to the Department of critical care medicine, the Third Hospital of Peking University from 2015 to 2019
You may qualify if:
- Pregnant patients admitted to the Department of critical care medicine, the Third Hospital of Peking University from 2015 to 2019
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Min Yi, chief physician
Peking University Third Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 29, 2021
First Posted
July 2, 2021
Study Start
August 1, 2021
Primary Completion
August 1, 2022
Study Completion
August 1, 2022
Last Updated
July 2, 2021
Record last verified: 2021-06